Agilent links with QIAGEN on drug discovery

Aug. 27, 2003 — Agilent Technologies Inc. and Qiagen NV have combined technologies in an effort to boost disease research and drug discovery, according to a news release.

The method combines Agilent’s 2100 Bioanalyzer for RNA, DNA and protein analysis, with Qiagen’s small interfering RNAs (siRNAs) technology. The siRNAs can be introduced into cells in order to silence, or block the function of selected genes to understand the role of their corresponding proteins — where drugs are likely to interact.

Palo Alto, Calif.-based Agilent and the Netherlands-based Qiagen also said they are working on other areas using microfluidics for gene silencing experiments.

Agilent, listed on the NYSE, closed at 24.00 Tuesday, down from 24.11 Monday. Qiagen, traded on Nasdaq, closed at 12.00 Tuesday, up from 11.48 Monday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.